Navigation Links
Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Date:8/1/2008

SAN DIEGO, Aug. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Bank of America 2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at 8:45 a.m. EDT (5:45 a.m. PDT). The conference is being held at the Southampton Inn in Long Island, New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through August 22, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
8. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... 09, 2017 , ... Each year in the United States more than 300,000 ... an independent lifestyle and, even worse, the one-year mortality rate is high, ranging from ... University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South ...
(Date:8/10/2017)... ... August 09, 2017 , ... SPIE, the international society for ... Wellman Center for Photomedicine, the Manstein Lab in the Cutaneous Biology Research Center ... at University of California, Irvine — and the Hillenkamp family to establish the ...
(Date:8/10/2017)... USA, and CARDIFF, UK (PRWEB) , ... August ... ... and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its exclusive ... SPIE as the exclusive sales representative for the SPIE Digital Library in Japan. ...
(Date:8/10/2017)... ... August 10, 2017 , ... BellBrook Labs announces the launch ... an enabling new high throughput screening (HTS) assay to aid researchers in their ... diseases. , Chemical modification of gene expression, also known as epigenetics, is perhaps ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):